Phraxis, Inc., a leader in vascular access innovation, announced the successful completion of the first commercial case using the EndoForce™ Anastomotic Connector, marking a historic milestone in the treatment of dialysis patients worldwide.
The procedure, performed by Dr. Ari Kramer, Vascular Access Surgeon and early clinical pioneer of EndoForce™, took place at Spartanburg Regional Medical Center in Spartanburg, South Carolina.
EndoForce™, recently granted U.S. Food and Drug Administration (FDA) approval, is the first device of its kind designed to simplify vascular access creation by replacing hand-sewn surgical sutures with a precise, reproducible connector. The technology is compatible with all PTFE grafts and was studied extensively in the company's pivotal clinical trial.
"Every decision we make in the OR comes back to the patient. With EndoForce™, we have a tool designed to make graft-to-vein connections more predictable and efficient. Launching the first commercial case at Spartanburg Regional is a meaningful step forward for our dialysis community," said Dr. Ari Kramer, Vascular Access Surgeon, Spartanburg Regional Medical Center.
"This achievement is the result of more than a decade of relentless innovation, collaboration with world-class surgeons, and unwavering commitment to patient outcomes. We are proud to see EndoForce™ enter the clinical arena—where it can make a meaningful difference," said Dr. Alex Yevzlin, Founder and Chief Executive Officer of Phraxis, Inc.
"Today represents more than a first commercial case—it's the beginning of a new standard in vascular access surgery. Dialysis patients deserve consistent, reliable solutions, and EndoForce is designed to deliver on that promise," added Geoffrey Beecher, Chief Commercial Officer of Phraxis, Inc.
The Spartanburg case marks the official start of U.S. commercialization for EndoForce™. Phraxis will continue to partner with leading vascular surgeons and health systems to expand availability, with additional clinical sites expected to begin cases in the coming months.
For more information, please visit www.phraxis.com.
